Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health Limited Receives Advanced and Overseas R&D Finding

09/13/2021 | 06:31pm EDT

ResApp Health Limited announced that it has received approval from AusIndustry for its application for an Advanced and Overseas Finding in respect to expenditure associated with its COVID-19 clinical studies. The finding covers financial years 2021, 2022 and 2023 and means that eligible overseas research and development expenditure in the company's COVID-19 clinical studies, in additional to Australian expenditure, will be subject to a 43.5% cash rebate under the Australian Federal Government's R&D Tax Incentive Program. The company now estimates that it will receive an R&D rebate of approximately $820,000 for the financial year ended 30 June 2021. In the US, the company is recruiting participants in a pilot study to collect data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone. Participants from this first study are also recruited into a second study which will collect additional cough sounds and data on disease progression to develop algorithms to remotely monitor patients with COVID-19.


© S&P Capital IQ 2021
All news about RESAPP HEALTH LIMITED
10/10RESAPP HEALTH : ReAapp Health Seeks US FDA Nod for Apnea Assessment Mobile App
MT
10/10RESAPP HEALTH : announces FDA 510(k) submission for SleepCheckRx
PU
10/10Resapp Announces FDA 510(K) Submission for Sleepcheckrx
CI
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
MT
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
PU
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
CI
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
MT
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
PU
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
CI
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
MT
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -5,08 M -5,08 M
Net cash 2021 6,40 M 4,80 M 4,80 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 55,8 M 42,0 M 41,9 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 80,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-21.18%43
SNAP INC.51.09%120 347
ANGI INC.-5.49%6 287
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-47.86%4 817
KAKAO GAMES CORP.54.35%4 503